Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $9.4 million.

  • Lineage Cell Therapeutics' Total Current Liabilities fell 3232.83% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 3232.83%. This contributed to the annual value of $14.0 million for FY2024, which is 2217.71% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Total Current Liabilities stood at $9.4 million for Q3 2025, which was down 3232.83% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Current Liabilities peaked at $47.1 million during Q4 2021, and registered a low of $6.6 million during Q1 2021.
  • For the 5-year period, Lineage Cell Therapeutics' Total Current Liabilities averaged around $16.9 million, with its median value being $15.9 million (2023).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Total Current Liabilities skyrocketed by 50646.16% in 2021 and then tumbled by 5971.43% in 2022.
  • Lineage Cell Therapeutics' Total Current Liabilities (Quarter) stood at $47.1 million in 2021, then crashed by 59.71% to $19.0 million in 2022, then decreased by 5.38% to $18.0 million in 2023, then decreased by 22.18% to $14.0 million in 2024, then crashed by 32.88% to $9.4 million in 2025.
  • Its Total Current Liabilities stands at $9.4 million for Q3 2025, versus $10.8 million for Q2 2025 and $13.1 million for Q1 2025.